ReviewMolecular neurobiology2025
The First 30 Days Postnatal of the GABA Receptor: A Comprehensive Overview.
Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rethinking GABAergic therapy in neonatal seizures: Beyond Scylla and Charybdis.Epilepsia open · 2026Article
- Ketogenic Strategies in Neonatal Hypoxic-Ischemic Encephalopathy-The Road to Opening Up: A Scoping Review.Neurology international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first 30 days postnatal represent a critical window for brain development in mammals. During this period, the gamma-aminobutyric acid (GABA) receptor undergoes significant functional and structural changes that are pivotal for neuronal maturation, synaptogenesis, and network stabilization. This article provides a comprehensive overview on the postnatal development of GABA receptors, highlighting their roles in inhibitory neurotransmission, developmental plasticity, and the transition from excitatory to inhibitory signaling. We also discuss the implications of dysregulated GABAergic signaling in neurodevelopmental disorders and the potential for therapeutic interventions.
Indexed as
Identifiers
41247442What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.